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Background. The role of hypertension as a kidney cancer
risk factor remains unclear. The objectives of this study were
to prospectively examine the effects of hypertension on kidney
cancer death, and to determine the synergistic effect of hyper-
tension and smoking on kidney cancer risk.
Methods. The cohort was composed of 576,562 Korean men,
aged 30 and older, who received health insurance from the Na-
tional Health Insurance Corporation, and who underwent bien-
nial medical evaluations in 1992 and 1994. At baseline, 343,132
men (59.5%) were identified as current cigarette smokers. Be-
tween 1995 and 2001, there were 92 deaths from kidney cancer
(2.2/100,000 person years). Using deaths from kidney cancer as
the main outcome variable, Cox proportional hazards models
were tested while controlling for age and other covariates.
Results. An initial finding indicated that hypertension in-
creased the mortality risk of kidney cancer [relative risk (RR)
2.43; 95% confidence interval (CI) 1.57–3.76]. After stratifica-
tion of smoking status, RR for hypertension on kidney cancer
was still increased for current smokers (RR 2.80; 95% CI 1.64–
4.79). For current smokers, those with systolic blood pressure
≥160 mm Hg had a risk of kidney cancer that was 8.18 (95%
CI, 3.13–21.36) times higher than those with a pressure less
than 120 mm Hg. When the interaction term was included in
the multivariate model, there was no significant synergistic ef-
fect of hypertension with current smoking on the risk of death
from kidney cancer.
Conclusion. This study supports the hypothesis that hyper-
tension is an independent risk factor of kidney cancer mortality.
It is well known that cancers are characterized by cell
proliferation. In addition, there is increasing evidence
that heightened cell proliferation occurs in many cardio-
vascular disorders, such as hypertension and atheroscle-
rosis [1], suggesting that hypertension shares at least some
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characteristics with the processes of abnormal cell prolif-
eration that are associated with cancer. Results of some
prospective cohort studies have suggested a modest, di-
rect association between blood pressure levels and the
overall risk of death from cancer [2–5]. Some investiga-
tors, however, argue that these results may have been af-
fected by confounding factors such as cigarette smoking
[6].
The hypothesis that hypertension increases the mortal-
ity risk of cancer is still under controversial discussion. In
this field there are two sub-hypotheses. First, the use of
antihypertensive drugs increases the risk of cancer, and
second, hypertension in itself is a significant risk factor
for cancer. An association between high blood pressure
and kidney cancer has been reported frequently [7, 8].
However, it is difficult to ascertain whether hypertension
produces or accelerates the development of renal cell car-
cinoma, or vice versa. Renal cell carcinoma is relatively
rare, accounting for approximately 3% of adult malig-
nancies, but its incidence and mortality have increased
internationally over the last 20 years, for reasons that re-
main unclear [9].
In this prospective study, therefore, we specifically
examined the relationship between hypertension and
kidney cancer, and investigated whether smoking may
interact with hypertension to heighten the risk of death
from kidney cancer.
METHODS
Study participants
The National Health Insurance Corporation (NHIC),
previously the Korean Medical Insurance Corporation
(KMIC), provides health insurance to government em-
ployees, teachers, and their dependents. Of the en-
tire Korean population—approximately 43.7 million in
1992—4,662,438 (10.7%) were insured by this organiza-
tion, consisting of 1,297,833 workers and their 3,364,605
dependents. All insured workers are encouraged to
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participate in regular, biennial medical examinations per-
formed by NHIC. In 1992 and 1994, 94% and 95% com-
pleted their biennial examinations, respectively.
This is an ongoing, prospective, cohort study designed
to assess the effects of hypertension on chronic diseases
in Korean men and women using the NHIC sample. Be-
cause only 0.6% of the women in this sample smoked,
we restricted our analyses to men. Of the 584,534 men
in the study, the 7972 smokers (1.7%) with incomplete
data on the amount and/or duration of smoking were ex-
cluded, yielding a final sample size of 576,562. Thus, the
final study cohort consisted of 576,562 men aged 30 and
older who underwent examinations in 1992 and 1994.
Data collection
NHIC biennial examinations are conducted in a stan-
dardized fashion by medical staff at designated local
hospitals or employment places. In the 1992 and 1994
data collection, participants were asked to describe
their smoking habits, including the number of cigarettes
smoked per day and the duration of cigarette smoking
in years, along with other lifestyle-related health habits,
including exercise and alcohol consumption. Completed
questionnaires were reviewed and edited by trained staff.
The 1992 and 1994 biennial medical examinations in-
cluded measurements of blood pressure, weight, height,
blood sugar, and serum cholesterol. Blood pressure was
measured in the seated position by a registered nurse or
trained hospital staff using a standard mercury sphyg-
momanometer or automatic manometer. In the case of
manual manometer use, systolic blood pressure (SBP)
and diastolic blood pressure (DBP) were measured at
the first and fifth Korotkoff sounds, respectively. A single
measurement was taken. A fasting blood specimen was
drawn and analyzed for blood sugar and total cholesterol.
Each hospital that participated in the examination fol-
lowed internal and external quality control procedures
directed by the Korean Association of Laboratory Qual-
ity Control. In our analysis, all participants had data on
blood pressure, total cholesterol, fasting serum glucose,
and body mass index (BMI) collected between 1992 and
1994.
Potential predictors of kidney cancer
Hypertension was defined as SBP ≥140 and/or DBP
≥90 mm Hg. We categorized blood pressure level ac-
cording to the guidelines of the Seventh Joint National
Committee (JNC VII) for the Detection, Evaluation,
and Treatment of High Blood Pressure (‘normal blood
pressure:’ SBP < 120 and DBP < 80 mm Hg; ‘pre-
hypertension:’ SBP 120–139 mm Hg or 80–89 DBP mm
Hg; ‘stage 1 hypertension:’ SBP 140–159 or DBP 90–
99 mm Hg; and ‘stage 2 hypertension:’ SBP ≥ 160 or
DBP 100 ≥ mm Hg) [10]. We defined diabetes accord-
ing to the National Diabetes Data Group’s diagnos-
tic criteria, revised in 1997 [11]. We considered par-
ticipants to have diabetes if they had a fasting blood
sugar ≥126 mg/dL, or if they were taking medications
for the treatment of diabetes. We defined hypercholes-
terolemia according to the National Cholesterol Edu-
cation Program (ATP III) guidelines (‘desirable:’ total
serum cholesterol <200 mg/dL; ‘borderline-high:’ total
serum cholesterol 200–239 mg/dL; and ‘high:’ total serum
cholesterol ≥240 mg/dL) [12]. BMI was calculated as
weight/height2 (kg/m2), and obesity was defined as BMI
at least 25 kg/m2. Categories of average daily alcohol con-
sumption were 0 g, 1 to 24 g, 25 to 49 g, 50 to 99 g, and more
than 100 g, as used in previous studies [13]. To reduce
measurement error, the average of the values obtained in
1992 and 1994 were used for estimation of an individual’s
baseline blood pressure, total cholesterol, fasting blood
sugar, weight, and height. We classified participants as
current smokers, ex-smokers, or nonsmokers.
Outcome ascertainment
The principal outcome variable was mortality from kid-
ney cancer. The follow-up period, which lasted 7 years,
was from January 1, 1995 to December 31, 2001. Out-
comes were ascertained from causes of death on death
certificates. In Korea, professionally trained and certi-
fied medical chart reviewers abstract charts and assign
discharge diagnoses in a standardized fashion. Likewise,
these reviewers complete death certificates using infor-
mation provided by individual doctors. Computerized
searches of death certificate data from the National Sta-
tistical Office in Korea were performed on each of the
KMIC-insured men. The system allowed near-perfect
availability of follow-up mortality data for participants
of this study.
Statistical analysis
Bivariate analyses provided information about the re-
lationship between hypertension and related factors such
as age, smoking status, BMI, alcohol use, diet, exercise,
diabetes, and total cholesterol and kidney cancer.
In order to assess the independent effects of smoking
(both current and former cigarettes smoking), hyperten-
sion, and interaction between smoking and hypertension
on kidney cancer events, Cox proportional hazard mod-
els were used. In each model, age, smoking status, BMI,
alcohol use, diet, exercise, diabetes, and total cholesterol
were controlled to delineate the independent effects of
smoking, hypertension, and possible interaction effects.
To calculate the population attributable risk (PAR) for
each risk factor, we used Levin’s formula [14]. In all anal-
yses, a two-sided alpha level of 0.05 was considered sta-
tistically significant.
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Table 1. Association between cardiovascular risk factors and kidney cancer: Follow-up from 1995 to 2001
Age-adjusted
Variable Person-years Kidney cancer Rate per 100,000 RR 95% CI P value
Age years 30–39 2,459,886 8 0.3 1.0
40–49 1,801,448 26 1.4 1.7 0.7–4.5 0.2611
50–59 1,358,733 47 3.5 1.3 0.3–5.2 0.6868
≥60 145,207 11 7.6 1.0 0.1–7.0 0.9649
Hypertension Normal 4,349,148 39 1.0 1.0
Hypertension 1,416,126 53 3.6 2.5 1.6–3.8 <.0001
Systolic blood pressure mm Hg <120 1,973,292 15 0.8 1.0
120–139 2,940,467 35 1.9 1.2 2.7–2.2 0.5341
140–159 685,425 30 3.7 2.9 1.5–5.4 0.0013
≥160 166,089 12 4.0 3.8 1.7–8.4 0.0008
Diastolic blood <80 2,146,024 15 0.7 1.0
pressure mm Hg 80–89 2,332,492 29 1.5 1.4 0.8–2.6 0.2854
90–99 986,464 30 3.3 2.5 1.3–4.7 0.0045
≥ 100 200,294 18 4.5 3.9 1.9–8.0 0.0001
Smoking status Nonsmoker 1,196,461 17 1.9 1.0
Ex-smoker 1,137,715 15 2.0 1.4 0.8–2.4 0.2241
Current smoker 3,431,098 60 2.4 0.8 0.4–1.7 0.5936
Body mass index kg/m2 <25 4,358,695 67 0.6 1.0
≥25 1,406,580 25 0.7 1.1 0.7–1.7 0.6925
Alcohol consumption g/day Nondrinker 1,057,468 11 1.1 1.0
1–24 3,843,912 65 2.4 1.9 1.0–3.6 0.0460
25–49 636,656 10 3.3 1.9 0.8–4.5 0.1337
50–99 183,762 5 2.5 3.2 1.1–9.3 0.0299
≥100 43,476 1 1.6 2.2 0.3–17.1 0.4481
Diabetes Normal 5,502,437 82 2.3 1.0
Diabetes 262,837 10 2.3 1.5 0.8–2.8 0.2704
Total serum <200 3,675,687 54 2.1 1.0
cholesterol mg/dL 200–240 1,667,935 27 2.3 1.1 0.5–1.6 0.3502
≥240 421,652 11 2.6 1.3 0.7–2.4 0.4308
Exercise No 4125793 55 2.3 1.0
Yes 1639481 37 2.3 0.9 0.6–1.4 0.5730
RESULTS
Among the 576,562 men, 434,930 (75.4%) were nor-
motensive, and 141,632 (24.6%) were hypertensive. The
mean (SD) age in the normotensive group was 41.5 (8.3),
and in the hypertensive group was 46.9 (8.8). During
the 7-year follow-up, there were 92 deaths from kidney
cancer.
Table 1 shows the degree of association observed be-
tween hypertension and other cardiovascular risk factors
in patients with kidney cancer followed from 1995 to 2001.
We found that age-adjusted mortality from kidney can-
cer was increased among the hypertensives, in association
with baseline level of both SBP and DBP.
After stratification for smoking status, Cox’s propor-
tional hazards model calculations indicated that the rel-
ative risk (RR) for hypertension increased for current
smokers (RR 2.80; 95% CI 1.64–4.79), suggesting that
hypertension exerted an increased effect only in combi-
nation with current smoking. This association was consis-
tently independent of age, alcohol consumption, diabetes,
total serum cholesterol, BMI, diet, and exercise (Table 2).
Compared with that in individuals with SBP < 120 mm
Hg, RR (95% CI) for kidney cancer mortality for those
with SBP greater than or equal to 160 mm Hg was 8.18
(3.13–21.36) in current smokers. However, there was no
significant association of level of hypertension with kid-
ney cancer in nonsmokers or ex-smokers.
The independent effect of hypertension on kidney can-
cer was examined in Cox’s proportional hazard models,
which simultaneously controlled for age, alcohol con-
sumption, diabetes, total serum cholesterol, BMI, diet,
and exercise (model 1 of Table 3). Compared with that
in normotensive individuals, RR for kidney cancer mor-
tality among hypertensive individuals was 2.43 (95% CI
1.57–3.76). When the interaction term was included in
a multivariate model, there was no interactive effect of
smoking with hypertension on kidney cancer (model 2 of
Table 3).
To assess the relationship between level of hyper-
tension and kidney cancer, we used Cox’s proportional
hazards models adjusted for age, smoking status, BMI,
alcohol use, diet, exercise, diabetes, and total cholesterol
(Fig. 1). Significant linear trends were observed in mor-
tality with increasing SBP and DBP levels for all cancer
and kidney cancer mortalities. At JNC VII level, those
with stage 3 hypertension had an increased risk of kidney
cancer (RR 3.87; 95% CI 1.79–8.4) compared with the
normotensive individuals.
For hypertension in men, we estimated the population-
attributable risks for kidney cancer, using hypertension
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Table 2. Effects of blood pressure on death from kidney cancer: Follow-up from 1995 to 2001
Nonsmoker Ex-smoker Current smoker
RR 95% CI RR 95% CI RR 95% CI
Hypertension
Normal 1.0 1.0 1.0
Hypertension 1.36 0.50–3.70 2.66 0.87–8.12 2.80 1.64–4.79
Systolic BP mm Hg
≤119 1.0 1.0 1.0
120–139 0.46 0.12–1.79 1.24 0.32–4.81 1.52 0.67–3.44
140–159 1.52 0.42–5.46 1.12 0.20–6.15 3.96 1.67–9.35
≥160 NE 1.21 0.11–12.89 8.18 3.13–21.36
Diastolic BP mm Hg
≤79 1.0 1.0 1.0
80–89 2.20 0.46–10.49 0.35 0.06–1.95 1.61 0.73–3.59
90–99 2.20 0.43–11.34 1.74 0.44–6.79 2.80 1.23–6.36
≥100 0.79 0.07–9.12 2.26 0.44–11.54 6.08 2.53–14.59
NE, not estimated due to small sample. Adjusted for age, alcohol consumption, diabetes, total serum cholesterol, body mass index, diet, and exercise.
Table 3. Interaction effect of hypertension and smoking on kidney cancer risk. Follow-up from 1995–2001 in two models: model 1 excluding the
interaction terms and model 2 including the interaction terms
Model 1 Model 2
Variable RR 95% CI P value RR 95% CI P value
Age 5-year 1.27 0.96–1.68 0.0891 1.27 0.96–1.68 0.0905
Hypertension Normal 1.0 1.0
Hypertension 2.43 1.57–3.76 <.0001 1.72 0.66–4.49 0.2725
Ex-smoking Nonsmoker 1.0 1.0
Ex-smoker 0.79 0.40–1.59 0.5158 0.68 0.24–1.97 0.4807
Current smoking Nonsmoker 1.0 1.0
Current smoker 1.36 0.79–2.36 0.2697 1.04 0.47–2.33 0.9171
Interaction 1 Hypertension
Ex-smokera – – – 1.31 0.32–5.33 0.7087
Interaction 2 Hypertension
Current smokera – – – 1.59 0.54–4.70 0.3994
Drink status Nondrinker 1.0 1.0
Drinker 1.64 0.86–3.10 0.1317 1.64 0.86–3.11 0.1307
Diabetic mellitus Normal 1.0 1.0
Diabetes 1.28 0.66–2.48 0.4724 1.28 0.66–2.48 0.4729
Total serum <200 1.0 1.0
cholesterol mg/dL ≥200 1.16 0.62–2.19 0.6458 1.16 0.62–2.19 0.6431
Body mass <25 1.0 1.0
index kg/m2 ≥25 0.94 0.59–1.51 0.8062 0.95 0.59–1.51 0.8184
Vegetable Yes 1.0 1.0
No 0.77 0.49–1.21 0.2519 0.77 0.49–1.21 0.2537
Exercise Yes 1.0 1.0
No 0.86 0.56–1.31 0.4744 0.86 0.56–1.31 0.4751
(−2 Log L) 2323.3 2322.5
aRisk ratio (RRs) and 95% confidence intervals (CIs) from multivariate Cox proportional hazards models after adjusting for age, alcohol consumption, diabetes,
total serum cholesterol, body mass index, diet, and exercise.
prevalence estimates from this study. Hypertension ac-
counted for 14.0% of all cancer deaths and 31.8% of kid-
ney cancer deaths.
DISCUSSION
In this large, prospective cohort study of Korean men,
we documented that hypertension was a strong and inde-
pendent risk factor for kidney cancer mortality.
Several prospective epidemiologic studies have inves-
tigated whether hypertension is a significant risk factor
for cancer [1, 2, 6, 15, 16], although the results of these
studies have been inconsistent. Some investigators have
hypothesized that hypertension by itself may be a risk
factor for kidney cancer. Others have suggested that ma-
lignancy led to hypertension, because an increased risk
of malignancy was most pronounced among newly di-
agnosed hypertensive patients and occurred in organs
that potentially could have led to a rise in blood pres-
sure [5]. On the other hand, several prospective epidemi-
ologic studies have found hypertension to be a signifi-
cant risk factor for kidney cancer [3, 15, 17]. Raynor et
al [3], in a 17-year prospective study of cancer mortality
among male employees of an electric company, reported
that hypertension was associated with a significantly in-
creased risk of renal cell carcinoma, but not of other can-
cers. Grove et al [15], in a 20-year prospective study of
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Fig. 1. The relationship between level of hypertension and kidney
cancer.
a cohort of 8006 Japanese-American men, found no as-
sociation between blood pressure and cancer death, but
did find elevated blood pressure to be associated with
renal cell carcinoma. Fletcher et al [17] found increased
mortality from renal cell carcinoma among hypertension
patients, despite the lack of association between blood
pressure and death from all malignancies or from lung
cancer. Grossman et al [8] conducted a meta-analysis of
13 case-control studies, and concluded that hypertension
was associated with an increased risk of mortality from
cancer, particularly renal cell carcinoma.
These studies support the hypothesis of a relationship
between high blood pressure and renal cell carcinoma
and suggest that high blood pressure may result from ab-
normal cell activity.
Although most previous studies showed a positive as-
sociation between hypertension and cancer mortality in
general, reliable information about the association with
specific types of cancer is scarce. Even in the case of stud-
ies that have reported a positive association between hy-
pertension and a particular type of cancer [1, 3, 6, 16,
18, 19], the results have been criticized because of small
sample sizes and short follow-up periods.
To assess the potential blood pressure-cancer relation-
ship without some of the limitations that were identified
in previous studies, we undertook the following approach.
First, our study sample was relatively large, at more than
500,000. This large sample size provided sufficient power
to assess the effect of blood pressure on kidney cancer
while allowing us to control for other potential confound-
ing factors. As a result, we found a significant association
between hypertension and kidney cancer that was inde-
pendent of smoking and other covariates.
Second, in our analyses, we specifically focused on par-
titioning the effect of smoking on kidney cancer because
smoking is a well-known cause of kidney cancer. In our
study, after adjusting for age, smoking, and BMI, hyper-
tension slightly increased the kidney cancer mortality risk
(RR 2.43). After stratification by smoking status, hyper-
tension was found to increase the mortality risk of kidney
cancer for the current smoking group. These results sug-
gest that the coexistence of smoking and hypertension
increased the mortality risk of kidney cancer, rather than
each factor acting alone. However, when an interaction
term was added to the model, hypertension was found
to have no effect on kidney cancer, while the interaction
term was also not significant. This finding strongly sug-
gests that hypertension was an independent risk factor
on the increasing mortality risk from kidney cancer.
Third, our cohort study featured a 7-year follow-up pe-
riod. Some may argue that this time period is still rela-
tively short; nevertheless, it is appreciably longer than
that of previous studies. Moreover, this length of time
was sufficient to eliminate the effects of other chronic ill-
nesses or preclinical cancers at baseline, although the ma-
jority of our individuals were from a mobile and healthy
population, as enrollees of the worker’s health insurance
group.
The potential limitation of our study arises primar-
ily from the use of data collected for clinical purposes
as part of an insurance plan. The questionnaires pro-
vide self-reported smoking information without valida-
tion, and the necessity to exclude the responses from
Korean women, who are under social pressure to under-
report their smoking habit, was a further limitation. Addi-
tionally, cancer mortality is subject to misclassification on
death certificates, particularly with regard to attribution
to a particular site. The limitations of death certificate
data on cancer have been characterized in some coun-
tries, but we are uncertain as to the applicability of these
findings to Korea.
There were several mechanisms that have been re-
ported in the literature to explain that correlation. It has
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been suggested that use of antihypertensive treatment
may be carcinogenic and associated with increased can-
cer risk, particularly renal cancer [16, 20, 21]. Genetic
predisposition both to hypertension and to cancer is also
one possibility. One can begin by exploring the area of cell
proliferation, a common characteristic of cancer and hy-
pertension. In 1982, when Folkow et al [22] first suggested
that hypertension was also characterized by proliferation
of smooth muscle cells, this finding was regarded as only
an additional mechanism underlying the pathogenesis of
hypertension, and was not considered in relation to the
concept of cancer. However, with the rapid advances that
have been made in elucidating the pathogenesis of cardio-
vascular diseases through cellular and molecular meth-
ods, it has become evident that hypertension, atheroscle-
rosis, and cancers share, to some extent, similar cellular
and molecular characteristics [23–25]. Studies carried out
in animals indicate that the diuretic drugs hydrochloroth-
iazide and furosemide may have a carcinogenic effect on
the kidney [26, 27], as well as on other organs, although
the effect is probably of small magnitude. In a recent thor-
ough meta-analysis, diuretic therapy was associated with
risk of renal cell carcinoma when compared with patients
not on diuretics [28].
CONCLUSION
Hypertension was a strong and independent risk factor
for kidney cancer. However, unresolved findings persist
concerning the interaction with other factors for kidney
cancer. Further studies should focus more on the plau-
sible physiologic mechanisms for cancer and the cancer-
causing risk factors.
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